Bal Pharma Ltd vs Morepen Laboratories Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 03, 2026

Key Highlights

The Latest Trading Price of Bal Pharma Ltd is ₹ 75.6 as of 30 Apr 15:30 . The P/E Ratio of Bal Pharma Ltd changed from 16.8 on March 2021 to 18.4 on March 2025 . This represents a CAGR of 1.84% over 5 yearsThe P/E Ratio of Morepen Laboratories Ltd changed from 14.9 on March 2021 to 22.3 on March 2025 . This represents a CAGR of 8.40% over 5 years The Market Cap of Bal Pharma Ltd changed from ₹ 79.67 crore on March 2021 to ₹ 132.4 crore on March 2025 . This represents a CAGR of 10.69% over 5 yearsThe Market Cap of Morepen Laboratories Ltd changed from ₹ 1446 crore on March 2021 to ₹ 2621 crore on March 2025 . This represents a CAGR of 12.64% over 5 years The revenue of Bal Pharma Ltd for the Dec '25 is ₹ 88.02 crore as compare to the Sep '25 revenue of ₹ 75.14 crore. This represent the growth of 17.14% The revenue of Morepen Laboratories Ltd for the Dec '25 is ₹ 487.97 crore as compare to the Sep '25 revenue of ₹ 442.04 crore. This represent the growth of 10.39% The ebitda of Bal Pharma Ltd for the Dec '25 is ₹ 9.87 crore as compare to the Sep '25 ebitda of ₹ 6.85 crore. This represent the growth of 44.09% The ebitda of Morepen Laboratories Ltd for the Dec '25 is ₹ 50.12 crore as compare to the Sep '25 ebitda of ₹ 61.16 crore. This represent the decline of -18.05% The net profit of Bal Pharma Ltd changed from ₹ 0.26 crore to ₹ 1.79 crore over 7 quarters. This represents a CAGR of 201.15% The net profit of Morepen Laboratories Ltd changed from ₹ 36.17 crore to ₹ 27.5 crore over 7 quarters. This represents a CAGR of -14.50% The Dividend Payout of Bal Pharma Ltd changed from 16.29 % on March 2021 to 24.49 % on March 2025 . This represents a CAGR of 8.50% over 5 yearsThe Dividend Payout of Morepen Laboratories Ltd changed from 10.79 % on March 2025 to 10.79 % on March 2025 . This represents a CAGR of 0.00% over 1 years .

About Bal Pharma Ltd

Bal Pharma Limited (BPL), a member of the Mcro Laboratories Group, was incorporated as a private limited company in May 1987.
In March 1990, BPL took over a pharmaceutical products manufacturing unit located in Bangalore through the Karnataka State Finance Corporation for a consideration of Rs 25.18 lac following which, BPL commenced manufacturing formulations. BPL manufactures and markets pharmaceutical formulations -- paracetamol, aluminium hydroxide, povidone iodine, alprazolam, gliclazide, griseofulvin, lactobacillus, rifampicin, piroxicam amoxycillin, etc.
The company promotes its products through the common sales force of the group but proposes to induct its own soon.
It came out with a public issue in Feb.'95 for manufacture of bulk drugs and expansion of pharmaceutical formulations.

About Morepen Laboratories Ltd

Morepen Laboratories Limited is an India-based pharmaceutical company.
Its products include Loratadine, Montelukast Sodium, Atorvastatin Calcium and Sultamicillin.
The company markets formulation products in various therapeutic categories, such as antibiotics, gastrointestinal, respiratory, analgesic, antiallergic and neuropsychiatry with brands, such as Saltum, Saltumax, Cefpopen, Cefpen-S, Dom-DT, Acifix, Rabipen- DSR and Montelast.
It has new products added to the therapeutic categories, including Kilbac, Ducal D, Aclomore and Montelast-L. The company has three state-of-the-art manufacturing plants in the northern state of Himachal Pradesh (HP) in India.
The main plant at Parwanoo is inspected and approved by United States Food and Drug Administration (USFDA) for production of Loratadine, which is the best selling anti-allergy drug globally.

FAQs for the comparison of Bal Pharma Ltd and Morepen Laboratories Ltd

Which company has a larger market capitalization, Bal Pharma Ltd or Morepen Laboratories Ltd?

Market cap of Bal Pharma Ltd is 120 Cr while Market cap of Morepen Laboratories Ltd is 2,269 Cr

What are the key factors driving the stock performance of Bal Pharma Ltd and Morepen Laboratories Ltd?

The stock performance of Bal Pharma Ltd and Morepen Laboratories Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Bal Pharma Ltd and Morepen Laboratories Ltd?

As of May 3, 2026, the Bal Pharma Ltd stock price is INR ₹75.6. On the other hand, Morepen Laboratories Ltd stock price is INR ₹41.41.

How do dividend payouts of Bal Pharma Ltd and Morepen Laboratories Ltd compare?

To compare the dividend payouts of Bal Pharma Ltd and Morepen Laboratories Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.